1. DSpace at My University
  2. E-Journal
  3. Teknologi Bank Darah
  4. Jurnal Internasional
  5. Journal of Microbiology, Immunology and Infection
  6. VOL 55 NO 1 2022
Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9146
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLan, Shao-Huan-
dc.contributor.authorLai, Chih-Cheng-
dc.contributor.authorChang, Shen-Peng-
dc.contributor.authorHsu, Chun-Chun-
dc.contributor.authorChen, Cheng-Hsin-
dc.contributor.authorWang, Ya-Hui-
dc.date.accessioned2024-12-17T03:01:00Z-
dc.date.available2024-12-17T03:01:00Z-
dc.date.issued2022-02-01-
dc.identifier.issn1684-1182-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9146-
dc.description.abstractAbstract Background: Anti-interleukin-5 (IL-5) therapy has been proposed as a novel treatment option for patients with chronic obstructive pulmonary disease (COPD). However, its efficacy for preventing COPD exacerbation remains unclear. Methods: A literature review was conducted to August 26th 2019. Only randomized controlled trials (RCTs) that investigated the clinical efficacy and adverse effects of anti-IL-5 therapy were included in the meta-analysis. The primary outcome was the risk of COPD exacerbation.en_US
dc.language.isoenen_US
dc.publisherElsevier Taiwan LLCen_US
dc.subjectCOPD;en_US
dc.subjectAnti-IL-5;en_US
dc.subjectMepolizumab;en_US
dc.subjectBenralizumab;en_US
dc.subjectEosinophilen_US
dc.titleEfficacy and safety of anti-interleukin-5 therapy in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized, controlled trialsen_US
dc.typeArticleen_US
Appears in Collections:VOL 55 NO 1 2022

Files in This Item:
File Description SizeFormat 
26-35.pdf2.86 MBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.